Exelixis is a biotechnology company focused on the development of small molecule therapies to treat cancer. The company’s proprietary resources and development efforts are focused exclusively on COMETRIQ, its lead product. The company has additionally established a portfolio of other novel compounds believed to have the potential to address serious unmet medical needs – many of which are being advanced through collaborations with partners. For more information, visit the company’s Web site at www.exelixis.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: